Work

PS5-09-23: A Phase 2 study of zelenectide pevedotin, a Bicycle Drug Conjugate, in patients with NECTIN4 amplified advanced breast cancer (Duravelo-3)

Year: 2026

Type: article

Study design: Study Protocol

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-09-23

Authors: P. A. Kaufman, P. Aftimos, J. Cortes, G. Curigliano, F. Dalenc, M. Danso, K. Jhaveri, M. Rimawi, C. Saura, P. Savas, P. Schmid, J. Ricker, K. Josephs, C. Xu, E. Hamilton

Institutions: University of Vermont, University of Vermont Medical Center, Université Libre de Bruxelles, Institut Jules Bordet, Universidad Europea de Madrid, University of Milan, European Institute of Oncology, Institut universitaire du cancer de Toulouse Oncopole, Virginia Oncology Associates, Memorial Sloan Kettering Cancer Center, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, The University of Melbourne, Peter MacCallum Cancer Centre, Queen Mary University of London, Barts Cancer Institute, Sarah Cannon

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129211980

FWCI:

Cites:

Cited by:

Related to: